December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era blockbuster). The stock last traded around $33.80, up roughly 9% from the prior close, with a market cap near $13 billion and a 52-week range roughly $22–$49. ^[1]

That jump comes as investors digest a fresh burst of pandemic-preparedness funding tied to Moderna’s H5 bird flu program—while, at the same time, headlines swirl around potential FDA actions on COVID-19 vaccine warnings. Put differently: Moderna stock is being priced on two timelines at once, and the market can’t…